Literature DB >> 19405865

Influence of loop electrosurgical excision procedure on subsequent acquisition of new human papillomavirus infections.

Philip E Castle1, Aimée R Kreimer, Sholom Wacholder, Cosette M Wheeler, Laura A Koutsky, Greg Rydzak, Dennis W Buckman, Barry Graubard, Mark Schiffman.   

Abstract

BACKGROUND: The impact of loop electrosurgical excision procedure (LEEP) treatment for cervical precancerous lesions on subsequent acquisition of new human papillomavirus (HPV) infections is not well described.
METHODS: The acquisition of new HPV infections was compared in HPV-positive women who underwent colposcopy and were treated by LEEP (n = 195) and those who were untreated (n = 1625) at entry into a 2-year study. Cumulative incidence rate ratios (IRRs) for treated versus untreated women at 6- and 24-months of follow-up, with 95% confidence intervals (CIs), were calculated for infection by individual HPV genotypes, any HPV genotypes, any carcinogenic HPV genotypes, any noncarcinogenic HPV genotypes, and phylogenetic groups of HPV genotypes.
RESULTS: Treated women were 29% less likely than untreated women to have carcinogenic HPV genotypes detected at 6-month follow-up visits (IRR, 0.71; 95% CI, 0.50-1.00) and were 18% less likely to have these genotypes detected at 24-month follow-up visits (IRR, 0.82; 95% CI, 0.68-1.01). Treated women were 56% less likely to have HPV genotypes of the alpha9 phylogenetic species (which includes HPV-16) detected at 6-month follow-up visits (IRR, 0.44; 95% CI, 0.23-0.85) and were 40% less likely to have these genotype detected at 24-month follow-up visits (IRR, 0.60; 95% CI, 0.42-0.85).
CONCLUSION: LEEP may reduce the acquisition of certain carcinogenic HPV genotypes related to HPV-16.

Entities:  

Mesh:

Year:  2009        PMID: 19405865      PMCID: PMC2790913          DOI: 10.1086/598981

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  36 in total

1.  Improved amplification of genital human papillomaviruses.

Authors:  P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial.

Authors:  D Solomon; M Schiffman; R Tarone
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

3.  ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants.

Authors:  M Schiffman; M E Adrianza
Journal:  Acta Cytol       Date:  2000 Sep-Oct       Impact factor: 2.319

4.  A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types.

Authors:  K L Liaw; A Hildesheim; R D Burk; P Gravitt; S Wacholder; M M Manos; D R Scott; M E Sherman; R J Kurman; A G Glass; S M Anderson; M Schiffman
Journal:  J Infect Dis       Date:  2000-11-16       Impact factor: 5.226

5.  Determinants of genital human papillomavirus detection in a US population.

Authors:  C L Peyton; P E Gravitt; W C Hunt; R S Hundley; M Zhao; R J Apple; C M Wheeler
Journal:  J Infect Dis       Date:  2001-05-09       Impact factor: 5.226

6.  A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women.

Authors:  Philip E Castle; Sholom Wacholder; Attila T Lorincz; David R Scott; Mark E Sherman; Andrew G Glass; Brenda B Rush; John E Schussler; Mark Schiffman
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

7.  Epidemiologic classification of human papillomavirus types associated with cervical cancer.

Authors:  Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

8.  Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students.

Authors:  Rachel L Winer; Shu-Kuang Lee; James P Hughes; Diane E Adam; Nancy B Kiviat; Laura A Koutsky
Journal:  Am J Epidemiol       Date:  2003-02-01       Impact factor: 4.897

9.  Prediction of recurrent disease by cytology and HPV testing after treatment of cervical intraepithelial neoplasia.

Authors:  A Aerssens; P Claeys; E Beerens; A Garcia; S Weyers; L Van Renterghem; M Praet; M Temmerman; R Velasquez; C A Cuvelier
Journal:  Cytopathology       Date:  2008-05-28       Impact factor: 2.073

10.  Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance.

Authors: 
Journal:  Am J Obstet Gynecol       Date:  2003-06       Impact factor: 8.661

View more
  4 in total

Review 1.  The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review.

Authors:  Anne F Rositch; Heidi M Soeters; Tabatha N Offutt-Powell; Bradford S Wheeler; Sylvia M Taylor; Jennifer S Smith
Journal:  Gynecol Oncol       Date:  2014-01-07       Impact factor: 5.482

2.  Reduced acquisition and reactivation of human papillomavirus infections among older women treated with cryotherapy: results from a randomized trial in South Africa.

Authors:  Sylvia Taylor; Chunhui Wang; Thomas C Wright; Lynette Denny; Wei-Yann Tsai; Louise Kuhn
Journal:  BMC Med       Date:  2010-06-29       Impact factor: 8.775

3.  Molecular progression to cervical precancer, epigenetic switch or sequential model?

Authors:  Belinda Nedjai; Caroline Reuter; Amar Ahmad; Rawinder Banwait; Rhian Warman; James Carton; Sabrina Boer; Jack Cuzick; Attila T Lorincz
Journal:  Int J Cancer       Date:  2018-07-03       Impact factor: 7.396

Review 4.  Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus.

Authors:  Maryam Dadar; Sandip Chakraborty; Kuldeep Dhama; Minakshi Prasad; Rekha Khandia; Sameer Hassan; Ashok Munjal; Ruchi Tiwari; Kumaragurubaran Karthik; Deepak Kumar; Hafiz M N Iqbal; Wanpen Chaicumpa
Journal:  Front Immunol       Date:  2018-11-12       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.